Merck & Co.'s first trial over the safety of its blockbuster cancer vaccine Gardasil was postponed mid-trial due to concerns that jurors might be influenced by media coverage surrounding the ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as ...

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

13 analysts have expressed a variety of opinions on Merck & Co (NYSE:MRK) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ...

(Reuters) - Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus vaccine in a case with ties to U.S. Department of Health ...

SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Merck & Co., Inc. (NYSE ...